NCBiotech News

When Heat Biologics licensed the immune system stimulating technology behind its ImPACT and ComPACT platforms from the University of Miami, it also licensed the tech behind Pelican Therapeutics Inc.

Wilmington physician Alan Brown, an impassioned inventor in his off hours, has transformed two of his ideas into award-winning product innovations – a self-illuminating speculum and a corneal marking system – designed to make eye surgeries more efficient and accurate, improving patient outcomes.

A group headlined by blazingly successful life science rainmaker Steve Butts, MBA, is hanging out a shingle in Morrisville, this time with $49 million in early funding support. They’re calling it Arrivo BioVentures.

Research Triangle Park startup CertiRx is teaming with a Croatian company, IN2trace Ltd., to combine its TraxSecur authentication technology with IN2trace’s CureCloud “serialization” technology into one software package, called TraxSecur Serialized Security.

Chapel Hill life science startup Rheomics, bootstrapped with a loan from the North Carolina Biotechnology Center, has won a $50,000 grant in the fall 2015 statewide NC IDEA competition.

All three of the life science startups competing in the current statewide NC IDEA competition have made it into the finals.

Phoundry Pharmaceuticals, a peptide drug-discovery startup in Research Triangle Park, will be acquired by Boston-based Intarcia Therapeutics for an undisclosed price only seven months after Phoundry was spun out of GlaxoSmithKline.

When a chorus of cheers accompanies announcements like the $1.85 billion Novo Nordisk expansion in Clayton, the echo is a reminder: it's a team effort.

Novo Nordisk, a key member of North Carolina’s globally significant biomanufacturing landscape, is adding a projected $1.85 billion expansion and doubling its workforce of 700 at its 22-year-old Clayton campus in Johnston County.

A high-profile collaboration announced today by Durham biopharmaceutical company Spyryx Biosciences is the latest in a string of breathtaking announcements by three young Durham companies with promising treatments for deadly lung diseases.

Timothy “Timm” Crowder, Ph.D., an entrepreneurial expert in design and development of inhaler technologies for lung therapies, has joined pharmaceutical startup Spyryx Biosciences as vice president of technical operations.

A $50,000 startup loan from the North Carolina Biotechnology Center has helped a young Chapel Hill pharmaceutical developer, Spyryx Biosciences, secure an $18 million Series A investment from a venture capital syndicate.

A potential new topical therapy for the treatment of acute migraine appears safe and effective, according to data that Achelios Therapeutics of Chapel Hill has prepared for presentation at an April 22 neurology conference.

An expanding group of investors has put $50 million worth of skin in the game for Durham-based dermatology products developer Novan Therapeutics.

As we weigh the GSK layoff announcement, let’s be glad for what we have and celebrate what’s to come. Sure, things will never be the same. But the fact is, they never were anyway.